Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06532591
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-04-10
Brief Title:
NeoadjuvantAdjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Neoadjuvant or Adjuvant Cadonilimab PD-1CTLA-4 Bispecific Antibody Plus Chemotherapy in Patients With Resectable Stage IB 4 cm to IIIBN2 PD-L1 Negative Non-small Cell Lung Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to observe and evaluate the efficacy and safety of cadonilimab combined with chemotherapy in patients with resectable IB 4cm - IIIB N2 stage PD-L1 negative non-small cell lung cancer
Detailed Description:
This study is design to prospectively investigate the safety and efficacy of cadonilimab combined with chemotherapy in patients with resectable IB 4cm - IIIB N2 stage PD-L1 negative NSCLC This is a single-institution single-arm phase 2 clinical trial Patients will receive 3 cycles of neoadjuvant chemotherapy The surgery was performed 3-6 weeks after the completion of neoadjuvant chemotherapy After surgery patients could receive up to 12 months of adjuvant chemotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None